Trials / Completed
CompletedNCT01426230
Phase IV Study of FDA Approved, Once-Daily GRALISE™(Gabapentin) Tablets for the Treatment of Postherpetic Neuralgia
A Phase 4, Open Label, Study of Safety and Effectiveness of GRALISE™(Gabapentin) Tablets in the Treatment of Patients With Postherpetic Neuralgia in Clinical Practice
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 201 (actual)
- Sponsor
- Depomed · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study objective is to assess the safety and effectiveness of once- daily GRALISE in clinical practice
Detailed description
Open Label, single arm, 2wk titration, 6 wk stable dosing, 8 wk of total treatment, 1wk dose tapering
Conditions
Timeline
- Start date
- 2011-09-01
- Primary completion
- 2012-03-01
- Completion
- 2012-04-01
- First posted
- 2011-08-31
- Last updated
- 2013-03-21
- Results posted
- 2013-03-21
Locations
37 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01426230. Inclusion in this directory is not an endorsement.